Hansa Biopharma has entered an exclusive licensing agreement with SERB S.A. for the development and commercialization of IDEFIRIX (imlifidase) across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and MENA regions. This deal includes an upfront payment of €110 million and an additional €5 million upon EMA filing acceptance, significantly strengthening Hansa's financial position and supporting its planned US launch pending FDA approval in 2026. IDEFIRIX is a pioneering treatment for highly sensitized kidney transplant patients, conditionally approved in Europe, offering a breakthrough for patients with limited options. SERB's established commercial presence in these regions is expected to enhance IDEFIRIX's market reach and clinical impact.
U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...
Accel Entertainment has maintained steady earnings growth and strong video gaming terminal distribution outside Illinois, but its stock remains rangebound since mid-2023. The company faces limited near-term upside due to higher operating costs and un...
The Vanguard Utilities Index Fund ETF (VPU) is rated a Buy, with a projected return of 12-14%. This positive outlook is driven by a $1.3 trillion capital expenditure cycle fueled by rising electricity demand from AI data centers. The CapEx cycle supp...
Avacta Therapeutics posted a £38.6 million loss for 2025 amid strategic focus on its proprietary pre|CISION® cancer drug platform. The company progressed two clinical-stage programs, AVA6000 and AVA6103, showing promising safety and efficacy data, es...
AI Financial Corp. disclosed that its $706 million WLFI token treasury is locked and unavailable for sale, raising serious liquidity and going concern issues. The company acquired 7.28 billion WLFI tokens in a $1.5 billion deal but the token value ha...
